Research__O into__O Health__B-ORG Technology__I-ORG Assessment__I-ORG (HTA)__I-ORG undertaken__O at__O Liverpool__B-ORG has__O led__O to__O significant__O impacts__O at__O the__O local,__O national__O and__O global__O levels.__O
Local__O Level__B-PER Impact.__I-PER
Liverpool__B-ORG provides__O Health__B-ORG Economics__I-ORG support__O to__O the__O Liverpool__B-ORG Clinical__I-ORG Trials__I-ORG Unit__I-ORG (LCTU),__I-ORG the__O largest__O CTU__O in__O the__O North__B-LOC West.__I-LOC
Each__O proposal__O for__O clinical__O research,__O submitted__O to__O LCTU,__B-ORG is__O assessed__O in__O terms__O of__O the__O quality__O of__O its__O Health__B-ORG Economics__I-ORG content__O and,__O in__O appropriate__O circumstances,__O the__O health__O economics__O research__O component__O is__O improved__O or__O added__O to__O the__O trial__O design.__O
Through__O this__O work,__O as__O well__O as__O relationships__O with__O local__O providers__O and__O commissioners__O of__O healthcare,__O Liverpool__B-ORG research__O has__O optimised__O resources__O allocated__O to__O a__O wide__O range__O of__O therapeutic__O areas.__O
These__O areas__O extend__O from__O evaluating__O the__O Liverpool__B-ORG care__O pathway__O in__O end__O of__O life__O care__O to__O a__O range__O of__O research__O projects__O with__O Liverpool__B-ORG Women's__I-ORG hospital__O in__O the__O fields__O of__O paediatric__O and__O neonatal__O medicine.__O
The__O corroboration__O offered__O by__O Wirral__B-ORG Primary__I-ORG Care__I-ORG Trust__I-ORG (Wirral__I-ORG PCT),__I-ORG a__O healthcare__O commissioner__O with__O whom__O Liverpool__B-ORG researchers__O have__O worked__O particularly__O closely,__O is__O evidence__O of__O Liverpool__B-ORG research__O directly__O impacting__O on__O the__O optimisation__O of__O healthcare__O resource__O allocation__O for__O local__O populations,__O both__O in__O terms__O of__O the__O optimisation__O of__O local__O commissioning__O and__O the__O provision__O of__O care__O in__O a__O wide__O range__O of__O particular__O patient__O groups__O and__O therapeutic__O areas__O (section__O 5.2).__O
National__B-ORG Level__I-ORG Impact.__I-ORG
HTA__B-ORG research__O at__O Liverpool__B-ORG has__O played__O an__O important__O role__O is__O establishing__O the__O policy__O and__O practice__O of__O drug__O adoption__O in__O the__O NHS.__B-LOC
As__O an__O independent__O academic__O unit__O funded__O by__O NHS__B-ORG R&amp;D,__I-ORG and__O working__O directly__O with__O NICE,__B-ORG the__O research__O that__O it__O undertakes__O has__O a__O direct__O and__O significant__O impact__O on__O healthcare__O provision__O within__O the__O UK.__B-ORG
Each__O of__O the__O research__O projects__O identified__O in__O section__O 2,__O has__O led__O directly__O to__O a__O change__O in__O national__O policy__O (Section__B-ORG 5.1)__O in__O order__O to__O enhance__O the__O provision__O of__O health__O care__O in__O a__O range__O of__O therapeutic__O areas,__O including__O thrombolysis,__O treatment__O of__O insomnia,__O malignant__O mesothelioma__O and__O coronary__O artery__O disease.__O
For__O example,__O by__O identifying__O the__O optimal__O relationship__O between__O resource__O allocation__O and__O clinical__O pathways__O and__O outcomes,__O for__O patients__O suffering__O a__O heart__O attack,__O the__O research__O emphasised__O the__O importance__O of__O providing__O patients__O with__O access__O to__O Thrombolysis__B-PER during__O the__O one__O hour__O period__O (the__O 'golden__O hour')__O following__O the__O attack.__O
Additionally,__O the__O research__O into__O treatment__O for__O insomnia__O (Section__B-ORG 3.3)__O identified__O that__O new__O drugs__O (the__O 'Z'__B-ORG drugs)__O were__O found__O to__O be__O of__O limited__O clinical__O effectiveness__O and__O did__O not__O provide__O 'value__O for__O money'__O for__O the__O NHS.__B-LOC
As__O a__O consequence__O of__O his__O international__O reputation__O as__O a__O research__O leader,__O Dr.__B-PER Haycox__I-PER was__O invited__O to__O join__O the__O NICE__B-ORG Appraisal__I-ORG Committee__I-ORG in__O 2008,__O and__O his__O role__O in__O NICE__B-ORG has__O been__O crucial__O in__O extending__O the__O impact__O of__O the__O research__O undertaken__O at__O Liverpool__B-ORG globally.__O
International__B-MISC Level__I-MISC Impact.__I-MISC
Liverpool__B-ORG has__O contributed__O substantially__O to__O International__B-MISC Healthcare__I-MISC Policy;__I-MISC specifically__O research__O in__O South__B-LOC East__I-LOC Asia,__B-LOC North__I-LOC Africa__I-LOC and__O Central__B-ORG Eastern__I-ORG Europe,__I-ORG facilitating__O the__O implementation__O of__O structures__O and__O skills__O of__O HTA__B-ORG that__O optimise__O the__O introduction__O of__O new__O drugs__O into__O national__O healthcare__O systems.__O
Many__O of__O the__O health__O systems__O of__O low__O to__O middle__O income__O countries__O are__O in__O flux__O with__O regard__O to__O the__O nature__O and__O structure__O of__O their__O healthcare__O systems.__O
HTA__B-ORG research__O at__O Liverpool__B-ORG has__O impacted__O on__O health__O systems__O in__O countries__O of__O North__B-LOC Africa__I-LOC and__O South__B-LOC East__I-LOC Asia__I-LOC favouring__O a__O move__O towards__O universal__O health__O coverage__O rather__O than__O a__O more__O 'market'__O oriented__O approach.__O
In__O support__O of__O universal__O coverage,__O Liverpool__B-ORG research__O has__O been__O helped__O to__O champion__O the__O use__O of__O structures__O of__O Health__B-ORG Technology__I-ORG Assessment__I-ORG as__O a__O 'rationing'__O device__O to__O maintain__O healthcare__O expenditure__O within__O sustainable__O levels.__O
Health__O technologies__O that__O are__O introduced__O into__O a__O health__O system__O that__O provides__O universal__O coverage__O serve__O all__O of__O the__O population__O and__O not__O just__O the__O rich,__O so__O HTA__B-ORG provides__O a__O mechanism__O by__O which__O to__O allocate__O scarce__O healthcare__O resources.__O
To__O facilitate__O this,__O Liverpool__B-ORG developed__O research-based__O guidance__O concerning__O optimal__O structures__O of__O HTA__B-ORG to__O support__O the__O establishment__O of__O universal__O health__O coverage__O in__O Indonesia__B-LOC and__O Egypt.__B-LOC
Another__O crucial__O element__O of__O such__O guidance__O was__O to__O identify__O the__O skills__O and__O expertise__O that__O must__O be__O developed__O within__O national__O research-based__O academic__O groups__O to__O support__O the__O establishment__O of__O effective__O systems__O of__O HTA.__B-LOC
The__O contribution__O of__O Liverpool__B-ORG to__O research-based__O policy__O and__O skills__O development__O is__O widespread,__O with__O exemplars__O to__O demonstrate__O the__O impact__O and__O reach__O of__O the__O research__O in__O three__O areas:__O Central__B-ORG and__O Eastern__B-LOC Europe__I-LOC (CEE),__I-LOC South__I-LOC East__I-LOC Asia__I-LOC (specifically__O Indonesia)__B-MISC and__O North__B-LOC Africa__I-LOC (specifically__O Egypt).__B-LOC
The__O impact__O and__O reach__O of__O HTA__B-ORG research__O at__O Liverpool__B-ORG has__O been__O extended__O through__O collaborative__O relationships__O with__O Pharmaceutical__B-PER Companies.__I-PER
A__O particularly__O close__O collaborative__O partnership__O with__O Novartis__O (the__O second__O largest__O drug__O company__O in__O the__O world),__O at__O both__O the__O national__O and__O global__O level,__O has__O been__O instrumental__O to__O diffusing__O the__O Liverpool__B-ORG HTA__B-ORG research__O to__O inform__O policy__O and__O practice__O in__O North__B-LOC Africa__I-LOC and__O South__B-LOC East__I-LOC Asia__I-LOC (Section__I-LOC 5.5).__O
Also,__O optimising__O the__O management__O of__O new__O medicines__O is__O a__O particular__O challenge__O for__O countries__O in__O CEE,__B-ORG given__O their__O limited__O experience__O of__O market-based__O healthcare__O provision.__O
The__O Piperska__B-ORG alliance,__O led__O by__O Liverpool,__B-LOC has__O developed__O research-based__O collaborations__O between__O leading__O academics__O and__O policy__O makers__O from__O Poland,__B-PER the__O Czech__B-ORG Republic,__I-ORG Slovakia,__I-ORG Slovenia,__I-ORG Latvia,__I-ORG Lithuania,__I-ORG Estonia,__I-ORG Serbia,__I-ORG and__O Turkey.__B-LOC
This__O has__O led__O to__O enhanced__O HTA__B-ORG research__O structures__O being__O established__O in__O many__O CEE__B-ORG countries__O leading__O to__O greater__O control__O on__O the__O introduction__O of__O new__O drugs__O and__O a__O consequent__O improvement__O in__O resource__O allocation__O and__O population__O health__O (for__O further__O details__O see__O Section__B-LOC 3.6;__O Section__B-ORG 5.5).__O
The__O principal__O beneficiaries__O of__O the__O impacts__O are:__O Patients__O in__O the__O UK,__B-ORG through__O the__O use__O of__O research-based__O HTA__O to__O target__O resources__O on__O interventions__O of__O proven__O clinical__O and__O cost__O effectiveness;__O Healthcare__O practitioners,__O both__O managerial__O and__O clinical,__O in__O the__O UK,__B-ORG through__O the__O establishment__O of__O optimal__O structures__O of__O healthcare__O provision__O based__O entirely__O on__O research-based__O evidence;__O Pharmaceutical__B-ORG companies__O through__O joint__O research-based__O HTA__B-ORG projects__O which__O independently__O evaluate__O the__O clinical__O and__O cost__O effectiveness__O of__O new__O drugs;__O Patients__O in__O SEA,__B-LOC North__I-LOC Africa__I-LOC and__O CEE,__B-ORG through__O the__O optimisation__O of__O healthcare__O provision__O to__O support__O the__O establishment__O of__O universal__O healthcare__O coverage;__O Health__O services__O within__O SEA,__B-ORG North__I-ORG Africa__I-ORG and__O CEE__B-ORG through__O joint__O research__O and__O training__O initiatives.__O
